{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:11:37Z","timestamp":1788757897699,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To provide a detailed analysis regarding survival, local control and toxicity of nodal\/bone oligo-recurrent prostate cancer identified and treated with PSMA-PET\/CT and robotic SBRT using a uniform dose\/fractionation scheme. The use of ADT was excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of patients with initial high-risk factors presenting with nodal\/bone oligo-recurrent PCA in Ga68- or F18-PSMA-PET\/CT treated with 1-3 fraction robotic SBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>60 patients\/172 metastases were treated in 95 treatment series with 43 patients receiving &amp;gt;1 SBRT course. Median FU was 22 months. bPFS\/SBRT-FS\/ADT-FS was 6\/23\/32 months at 89.7% local control and 6.5\/1.1% acute\/late grade 1\u00a0AE. High PSA-nadir, initial pN1-status and longer time to PSA-nadir were predictive for worse bPFS\/SBRT-FS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Metastasis-Directed-Therapy using ablative focal SBRT is effective in bridging the gap between the identification of early metastases and the initiation of palliative systemic therapy. It is a fast outpatient procedure yielding high rates of local control, free of significant toxicity and repeatable if necessary. ADT could be withheld for almost 3 years. Patients with predictors for worse outcome could be identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1738508","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:23:52Z","timestamp":1788755032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer"],"prefix":"10.3389","volume":"6","author":[{"given":"Arne","family":"Gr\u00fcn","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Partyka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Galler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Schlomm","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"B\u00f6hmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Kalinauskaite","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1475914","article-title":"Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment","volume":"14","author":"Sch\u00fctz","year":"2024","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Meta-analysis of randomized trials in cancer of the prostate MARCAP Consortium investigators. Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.025","article-title":"Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer","volume":"84","author":"Sutera","year":"2023","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.02.010","article-title":"Predictors of recurrence after metastasis-directed therapy in oligorecurrent prostate cancer following radical prostatectomy","volume":"6","author":"Milenkovic","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1967\/s002449910952","article-title":"More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET\/CT","volume":"22","author":"Pianou","year":"2019","journal-title":"Hell J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2022.09.007","article-title":"Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers","volume":"6","author":"Huynh","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02082-w","article-title":"Radiotherapy concepts for spinal metastases-results from an online survey among radiation oncologists of the German Society for Radiation Oncology","volume":"200","author":"Waltenberger","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000707","article-title":"ACR-ASTRO practice parameter for communication: radiation oncology","volume":"43","author":"Schechter","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000706","article-title":"ACR-ASTRO practice parameter for the performance of stereotactic body radiation therapy","volume":"43","author":"Chao","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: a systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02254-2","article-title":"Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"200","author":"Brunner","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00066-024-02304-9","article-title":"Early and repetitive novel-tracer PET-guided stereotactic body radiotherapy for nodal oligorecurrent prostate cancer after definitive first-line therapy","volume":"201","author":"Gr\u00fcn","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1955970","article-title":"Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases","volume":"60","author":"Werensteijn-Honingh","year":"2021","journal-title":"Acta Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32509","article-title":"Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial","volume":"146","author":"Bowden","year":"2020","journal-title":"Int J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2021.02.008","article-title":"Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta-analysis of prospective studies","volume":"27","author":"Marvaso","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102239","article-title":"Salvage stereotactic radiotherapy for nodal oligo-recurrent prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Aman","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684629","article-title":"The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"296","author":"Tan","year":"2020","journal-title":"Radiology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-019-0156-z","article-title":"Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis","volume":"23","author":"Kimura","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2019.0817","article-title":"68Ga-prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis","volume":"47","author":"Matushita","year":"2021","journal-title":"Int Braz J Urol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.08.002","article-title":"Metastasis-directed therapy (SBRT) guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness","volume":"19","author":"Mazzola","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.008","article-title":"Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience","volume":"105","author":"Deek","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-019-01523-9","article-title":"Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis","volume":"196","author":"Nicosia","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/jsxmed\/qdaf164","article-title":"Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients","volume":"22","author":"Nascimento","year":"2025","journal-title":"J Sex Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02193-4","article-title":"Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)","volume":"200","author":"Koerber","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02129-y","article-title":"Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer-long-term data from the prospective PLATIN-2 trial","volume":"200","author":"Fink","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.020","article-title":"Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07)","volume":"103","author":"Vaugier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-021-01871-5","article-title":"Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes","volume":"198","author":"Cozzi","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01629-5","article-title":"Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy","volume":"196","author":"Henkenberens","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-022-10157-8","article-title":"PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study","volume":"39","author":"Mazzola","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V\u2013STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12032-021-01518-6","article-title":"Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance","volume":"38","author":"Triggiani","year":"2021","journal-title":"Med Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.06.2720","article-title":"Comparative analysis of lymph node-only vs. bone-only metastasis-directed radiation therapy in oligorecurrent prostate cancer","volume":"123","author":"Aslot","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.160","article-title":"PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer","volume":"43","author":"Francolini","year":"2025","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2522981","article-title":"The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data","volume":"25","author":"Zhang","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MOU.0000000000001313","article-title":"Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy","volume":"35","author":"Falagario","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B60","volume-title":"Eau Guidelines","year":"2026"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000113794.34810.d0","article-title":"Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy","volume":"171","author":"Moul","year":"2004","journal-title":"J Urol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer (EORTC) trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomized, multicenter, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-01925-2","article-title":"Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO)","volume":"198","author":"Rogowski","year":"2022","journal-title":"Strahlenther Onkol"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1738508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:23:54Z","timestamp":1788755034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1738508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":64,"alternative-id":["10.3389\/fruro.2026.1738508"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1738508","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1738508"}}